Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data
Details : Documents supporting drugmaker Uniao Quimica’s application for emergency use of Sputnik V have been returned to the company because they did not meet its minimum criteria.
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
January 17, 2021
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Study With Heparin Sodium in Intravenous Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2017
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Amblyomin-X in Advanced Solid Tumor
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 19, 2017
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Study With Heparin Sodium in Subcutaneous Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2017
Lead Product(s) : Heparin Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Buranello e Rodrigues Consultoria
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 29, 2011
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Recipient : Azidus Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
